Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$103.34 USD
-1.08 (-1.03%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $103.33 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 361 - 380 ( 512 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ASH 2019: Key Presentations Roundup for Covered Companies Days 1-2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
R-D day Highlights key Development Efforts in the Coming Years; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Systemic Mastocytosis in Focus at R-D Day, PIONEER at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
A Valentine?s Day Breakup; FDA Splits Ava NDA - Waits for VOYAGER 4L GIST Data
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-782 Licensed Out as Ipsen Doubles Down on FOP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
EMSO 2019 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Selpercatinib Update Pressures Pralsetinib to Perform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department